New Collaboration to Assess Specificity of Postpartum Depression Biomarker Signature

Brisbane, Australia – March 11, 2026 – Ketim Technologies has initiated a new research collaboration with the Thompson Institute at the University of the Sunshine Coast to evaluate the specificity of its postpartum depression (PPD) biomarker signature.

Following completion of its discovery study and identification of a protein-based risk signature for postpartum depression, Ketim is now expanding validation efforts to determine whether the identified biomarkers are specific to perinatal mental illness or reflect broader psychiatric biology.

The collaboration will analyse samples from individuals diagnosed with post-traumatic stress disorder (PTSD), depression, and anxiety outside of pregnancy. This comparative analysis aims to clarify whether Ketim’s PPD risk signature represents a pregnancy-specific biological signal or a shared molecular architecture across psychiatric conditions.

The dataset also includes participants receiving pharmacological treatment, enabling exploratory analysis of proteomic markers associated with treatment response.

This next phase strengthens Ketim’s precision medicine approach by ensuring rigorous differentiation between perinatal-specific biomarkers and general psychiatric signatures.

The collaboration reflects Ketim’s ongoing commitment to advancing biomarker-driven diagnostics that are both scientifically robust and clinically meaningful.

For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au